1. Home
  2. BBIO vs PET Comparison

BBIO vs PET Comparison

Compare BBIO & PET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • PET
  • Stock Information
  • Founded
  • BBIO 2015
  • PET 2015
  • Country
  • BBIO United States
  • PET United States
  • Employees
  • BBIO N/A
  • PET N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • PET EDP Services
  • Sector
  • BBIO Health Care
  • PET Technology
  • Exchange
  • BBIO Nasdaq
  • PET Nasdaq
  • Market Cap
  • BBIO 6.7B
  • PET 8.4M
  • IPO Year
  • BBIO 2019
  • PET N/A
  • Fundamental
  • Price
  • BBIO $34.37
  • PET $0.14
  • Analyst Decision
  • BBIO Strong Buy
  • PET Strong Buy
  • Analyst Count
  • BBIO 12
  • PET 5
  • Target Price
  • BBIO $57.09
  • PET $4.90
  • AVG Volume (30 Days)
  • BBIO 3.2M
  • PET 11.3M
  • Earning Date
  • BBIO 04-29-2025
  • PET 05-12-2025
  • Dividend Yield
  • BBIO N/A
  • PET N/A
  • EPS Growth
  • BBIO N/A
  • PET N/A
  • EPS
  • BBIO N/A
  • PET N/A
  • Revenue
  • BBIO $127,415,000.00
  • PET $70,507,000.00
  • Revenue This Year
  • BBIO $13.67
  • PET $7.87
  • Revenue Next Year
  • BBIO $118.02
  • PET $122.23
  • P/E Ratio
  • BBIO N/A
  • PET N/A
  • Revenue Growth
  • BBIO N/A
  • PET N/A
  • 52 Week Low
  • BBIO $21.62
  • PET $0.08
  • 52 Week High
  • BBIO $39.47
  • PET $2.47
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 49.67
  • PET 47.48
  • Support Level
  • BBIO $33.92
  • PET $0.14
  • Resistance Level
  • BBIO $39.16
  • PET $0.16
  • Average True Range (ATR)
  • BBIO 1.43
  • PET 0.03
  • MACD
  • BBIO -0.16
  • PET 0.01
  • Stochastic Oscillator
  • BBIO 31.05
  • PET 49.63

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About PET Wag! Group Co.

Wag Group Co develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent Pet Caregivers to connect with pet parents. The platform allows pet parents to make pet service requests in the platform, which can then be fulfilled by Pet Caregivers. Wag supports dog walking, pet sitting, pet boarding, drop-in visits at the pet parent's home, advice from licensed pet experts, training services, pet insurance comparison tools and pet wellness plans.

Share on Social Networks: